Treats osteoarthritis of the knee(s). ANDA 204132, held by Lupin. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 204132 (Diclofenac Sodium), held by Lupin, was first approved by FDA on Aug 20, 2015, with 4 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 20, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium1.5% · solution;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 24, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 14, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 20, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters